(often searched as VENX-201) is a novel, investigational therapy being developed by Ventoux Biosciences to treat fibrotic diseases , specifically focusing on Dupuytren’s disease .
: The drug is designed for direct injection into fibrotic tissue, which maximizes local effectiveness while minimizing systemic side effects. Target Indications : VENX-201
Ventus Therapeutics has also expressed interest in developing a (VENX-202) with optimized brain penetration and once-weekly dosing, but VENX-201 remains the lead asset. (often searched as VENX-201) is a novel, investigational
By binding to NLRP3 and locking it in an inactive conformation, it prevents: GitHub)? The general goal
: A base-editing medicine targeting the ANGPTL3 gene to treat cardiovascular disease.
where this ticket is hosted (e.g., Jira, Azure DevOps, GitHub)? The general goal